GlassScriptPhysician profile
Sherif S Iskander
NPI 1255321980
$57,802.07
in general payments reported to CMS, 2019-2025
35 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $3,489 · 2021: $1,545 · 2022: $2,017 · 2023: $1,982 · 2024: $2,358 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,278 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,277.54 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17,980.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14,864.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,762.73 | 2019-2023 | Jardiance |
| Impulse Dynamics (USA) INC. | $1,615.50 | 2021-2024 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $1,191.88 | 2019-2024 | Xarelto |
| Biotronik INC. | $1,085.88 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $714.96 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $613.88 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $608.90 | 2019-2025 | Farxiga |
| Amgen INC. | $525.72 | 2019-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $469.14 | 2019-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $453.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $419.35 | 2019-2024 | Camzyos, Eliquis |
| Abiomed | $393.53 | 2022-2025 | |
| Abbott Laboratories | $328.08 | 2023-2025 | Mitraclip, Cardiomems |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $303.34 | 2024-2025 | Symplicity G3, Corevalve Evolut R |
| Angiodynamics, INC. | $289.18 | 2021-2025 | Auryon Laser System 100-120 Vac |
| Sanofi-Aventis U.S. LLC | $220.19 | 2019-2024 | |
| Novo Nordisk INC | $202.49 | 2021-2024 | Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $193.69 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $193.59 | 2019-2021 | |
| Atricure, INC. | $191.82 | 2019-2022 | |
| Lundbeck LLC | $179.77 | 2019 | |
| Shockwave Medical, INC | $168.15 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $150.22 | 2019-2023 | |
| Heartflow, INC. | $136.55 | 2023 | Ffrct |
| Gilead Sciences, INC. | $130.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.60 | 2022 | |
| Jazz Pharmaceuticals INC. | $109.85 | 2019 | |
| Esperion Therapeutics, INC. | $57.00 | 2020 | |
| Terumo Medical Corporation | $44.61 | 2023 | Glidesheath Slender, Tr Band |
| Kiniksa Pharmaceuticals International, Plc | $35.32 | 2024 | Arcalyst |
| Cvrx, INC. | $25.16 | 2022 | |
| Amarin Pharma, INC. | $13.69 | 2021 | |
| Siemens Medical Solutions USA, INC. | $13.47 | 2024 | Artis Icono Floor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherif Iskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.